Odepraz D 30mg/40mg Capsule SR is a combination medication containing Domperidone 30mg and Esomeprazole 40mg, formulated for sustained release to provide effective management of gastrointestinal disorders. Domperidone, a peripheral dopamine D2 receptor antagonist, enhances gastrointestinal motility by increasing the movement of the stomach and intestines, thereby facilitating gastric emptying and alleviating symptoms such as nausea, vomiting, and bloating. Esomeprazole, a proton pump inhibitor (PPI), suppresses gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme system in the gastric parietal cells, leading to reduced acid production and promoting healing of acid-related mucosal damage. The combined action of these agents makes Odepraz D suitable for the treatment of gastroesophageal reflux disease (GERD), erosive esophagitis, peptic ulcer disease, and functional dyspepsia, particularly in patients experiencing delayed gastric emptying or upper gastrointestinal motility disorders. The sustained-release formulation ensures prolonged therapeutic plasma concentrations, enhancing efficacy and patient compliance. Odepraz D should be used under medical supervision, with caution in patients with known hypersensitivity to its components, and is contraindicated in cases of gastrointestinal hemorrhage, mechanical obstruction, or prolactin-releasing pituitary tumors. Common side effects may include headache, dry mouth, and abdominal discomfort.